Drug Interactions

Comprehensive guide to drug-drug interactions, pharmacokinetic interactions, and interaction management.

Browse the pages below for detailed information.

ipragliflozin — Sodium/glucose cotransporter 2 Interaction

Drug-target interaction between ipragliflozin and Sodium/glucose cotransporter 2. Synthetic organic pharmacological agent targeting this protein.

ipratropium — M3 receptor Interaction

Drug-target interaction between ipratropium and M3 receptor. Synthetic organic pharmacological agent targeting this protein.

irbesartan — AT1 receptor Interaction

Drug-target interaction between irbesartan and AT1 receptor. Synthetic organic pharmacological agent targeting this protein.

irinotecan — DNA topoisomerase I Interaction

Drug-target interaction between irinotecan and DNA topoisomerase I. Synthetic organic pharmacological agent targeting this protein.

isatuximab — CD38 Interaction

Drug-target interaction between isatuximab and CD38. Antibody pharmacological agent targeting this protein.

isoprenaline — β1-adrenoceptor Interaction

Drug-target interaction between isoprenaline and β1-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.

isoprenaline — β2-adrenoceptor Interaction

Drug-target interaction between isoprenaline and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.

itolizumab — CD6 Interaction

Drug-target interaction between itolizumab and CD6. Antibody pharmacological agent targeting this protein.

ivosidenib — isocitrate dehydrogenase (NADP(+)) 1 Interaction

Drug-target interaction between ivosidenib and isocitrate dehydrogenase (NADP(+)) 1. Synthetic organic pharmacological agent targeting this protein.

ixabepilone — tubulin beta class I Interaction

Drug-target interaction between ixabepilone and tubulin beta class I. Synthetic organic pharmacological agent targeting this protein.

ixazomib — proteasome 20S subunit beta 5 Interaction

Drug-target interaction between ixazomib and proteasome 20S subunit beta 5. Synthetic organic pharmacological agent targeting this protein.

ketamine — GluN2A Interaction

Drug-target interaction between ketamine and GluN2A. Synthetic organic pharmacological agent targeting this protein.

ketamine — GluN2B Interaction

Drug-target interaction between ketamine and GluN2B. Synthetic organic pharmacological agent targeting this protein.

ketamine — GluN2C Interaction

Drug-target interaction between ketamine and GluN2C. Synthetic organic pharmacological agent targeting this protein.

ketamine — GluN2D Interaction

Drug-target interaction between ketamine and GluN2D. Synthetic organic pharmacological agent targeting this protein.

ketoprofen — COX-1 Interaction

Drug-target interaction between ketoprofen and COX-1. Synthetic organic pharmacological agent targeting this protein.

ketoprofen — COX-2 Interaction

Drug-target interaction between ketoprofen and COX-2. Synthetic organic pharmacological agent targeting this protein.

ketorolac — COX-1 Interaction

Drug-target interaction between ketorolac and COX-1. Synthetic organic pharmacological agent targeting this protein.

ketorolac — COX-2 Interaction

Drug-target interaction between ketorolac and COX-2. Synthetic organic pharmacological agent targeting this protein.

ketotifen — H1 receptor Interaction

Drug-target interaction between ketotifen and H1 receptor. Synthetic organic pharmacological agent targeting this protein.

labetalol — α1D-adrenoceptor Interaction

Drug-target interaction between labetalol and α1D-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.

labetalol — β1-adrenoceptor Interaction

Drug-target interaction between labetalol and β1-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.

labetalol — β2-adrenoceptor Interaction

Drug-target interaction between labetalol and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.

lacosamide — Nav1.7 Interaction

Drug-target interaction between lacosamide and Nav1.7. Synthetic organic pharmacological agent targeting this protein.

lanadelumab — kallikrein B1 Interaction

Drug-target interaction between lanadelumab and kallikrein B1. Antibody pharmacological agent targeting this protein.

lanreotide — SST2 receptor Interaction

Drug-target interaction between lanreotide and SST2 receptor. Peptide pharmacological agent targeting this protein.

lanreotide — SST5 receptor Interaction

Drug-target interaction between lanreotide and SST5 receptor. Peptide pharmacological agent targeting this protein.

lapatinib — epidermal growth factor receptor Interaction

Drug-target interaction between lapatinib and epidermal growth factor receptor. Synthetic organic pharmacological agent targeting this protein.

lapatinib — erb-b2 receptor tyrosine kinase 2 Interaction

Drug-target interaction between lapatinib and erb-b2 receptor tyrosine kinase 2. Synthetic organic pharmacological agent targeting this protein.

latanoprost (free acid form) — FP receptor Interaction

Drug-target interaction between latanoprost (free acid form) and FP receptor. Synthetic organic pharmacological agent targeting this protein.

latanoprost (isopropyl ester) — FP receptor Interaction

Drug-target interaction between latanoprost (isopropyl ester) and FP receptor. Synthetic organic pharmacological agent targeting this protein.

leflunomide — dihydroorotate dehydrogenase (quinone) Interaction

Drug-target interaction between leflunomide and dihydroorotate dehydrogenase (quinone). Synthetic organic pharmacological agent targeting this protein.

lemborexant — OX1 receptor Interaction

Drug-target interaction between lemborexant and OX1 receptor. Synthetic organic pharmacological agent targeting this protein.

lemborexant — OX2 receptor Interaction

Drug-target interaction between lemborexant and OX2 receptor. Synthetic organic pharmacological agent targeting this protein.

leniolisib — phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Interaction

Drug-target interaction between leniolisib and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta. Synthetic organic pharmacological agent targeting this protein.

lenvatinib — fms related receptor tyrosine kinase 4 Interaction

Drug-target interaction between lenvatinib and fms related receptor tyrosine kinase 4. Synthetic organic pharmacological agent targeting this protein.

lenvatinib — kinase insert domain receptor Interaction

Drug-target interaction between lenvatinib and kinase insert domain receptor. Synthetic organic pharmacological agent targeting this protein.

lepirudin — coagulation factor II, thrombin Interaction

Drug-target interaction between lepirudin and coagulation factor II, thrombin. Peptide pharmacological agent targeting this protein.

letrozole — CYP19A1 Interaction

Drug-target interaction between letrozole and CYP19A1. Synthetic organic pharmacological agent targeting this protein.

leuprolide — GnRH1 receptor Interaction

Drug-target interaction between leuprolide and GnRH1 receptor. Peptide pharmacological agent targeting this protein.

levallorphan — μ receptor Interaction

Drug-target interaction between levallorphan and μ receptor. Synthetic organic pharmacological agent targeting this protein.

levetiracetam — synaptic vesicle glycoprotein 2A Interaction

Drug-target interaction between levetiracetam and synaptic vesicle glycoprotein 2A. Synthetic organic pharmacological agent targeting this protein.

levomilnacipran — NET Interaction

Drug-target interaction between levomilnacipran and NET. Synthetic organic pharmacological agent targeting this protein.

levomilnacipran — SERT Interaction

Drug-target interaction between levomilnacipran and SERT. Synthetic organic pharmacological agent targeting this protein.

levonorgestrel — Progesterone receptor Interaction

Drug-target interaction between levonorgestrel and Progesterone receptor. Synthetic organic pharmacological agent targeting this protein.

levorphanol — μ receptor Interaction

Drug-target interaction between levorphanol and μ receptor. Synthetic organic pharmacological agent targeting this protein.

LH — LH receptor Interaction

Drug-target interaction between LH and LH receptor. Peptide pharmacological agent targeting this protein.

Li+ — IMPase 1 Interaction

Drug-target interaction between Li+ and IMPase 1. Inorganic pharmacological agent targeting this protein.

lidocaine — Nav1.5 Interaction

Drug-target interaction between lidocaine and Nav1.5. Synthetic organic pharmacological agent targeting this protein.

lifitegrast — integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) Interaction

Drug-target interaction between lifitegrast and integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide). Synthetic organic pharmacological agent t